IPN10200 for Migraine Prevention

(MERANTI Trial)

Recruiting at 167 trial locations

Overseen By Ipsen Clinical Study Enquiries

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Ipsen

Must not be taking: Opioids, Barbiturates, Cannabinoids, others

Disqualifiers: Uncontrolled psychiatric, Neuromuscular, Respiratory, others

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 2 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: Unknown

641 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new treatment called IPN10200 (also known as Botulinum toxin) to determine its safety and effectiveness in preventing migraines. The treatment involves injecting the medication into the head and neck muscles to block chemicals that trigger migraine pain. The trial seeks to identify the optimal dose that balances safety and effectiveness. Individuals with migraines, whether episodic (fewer than 15 headache days a month) or chronic (15 or more headache days a month), might be suitable for this study. Participants must maintain a daily electronic diary of their migraine occurrences. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of people.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but it does list certain medications that cannot be used before joining the study, like botulinum toxin, CGRP blockers, and some others. It's best to discuss your current medications with the study team to see if they might interfere with the trial.

Is there any evidence suggesting that IPN10200 is likely to be safe for humans?

Research has shown that treatments using botulinum toxin, such as IPN10200, are generally safe for preventing chronic migraines. Studies indicate that patients typically tolerate these treatments well, with some experiencing fewer side effects than those associated with migraine pills. However, mild side effects have been noted with botulinum toxin use. It's important to note that while the treatment appears promising, the current trial is only in the second phase, indicating that more information is needed about its safety and effectiveness. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising for migraines?

Researchers are excited about IPN10200 for migraine prevention because it offers a potentially novel approach compared to current treatments like triptans, beta-blockers, and CGRP inhibitors. Unlike these standard therapies, IPN10200 is administered via injection, which might provide longer-lasting relief with less frequent dosing. Additionally, if IPN10200 works through a new mechanism of action, it could target migraine pathways more effectively or differently, offering hope for patients who don’t respond well to existing medications. This innovative treatment could significantly enhance the quality of life for those suffering from chronic migraines.

What evidence suggests that IPN10200 might be an effective treatment for migraines?

Research shows that IPN10200 works by blocking the release of chemicals in the brain that cause migraine pain. This method resembles treatments like Botox, which has significantly reduced the number of headache days. Specifically, studies on Botox indicate it can result in eight fewer headache days each month. People using these treatments report less severe headaches and fewer missed days of work or daily activities. This trial will evaluate IPN10200 at different doses, and these findings suggest that IPN10200 could effectively reduce the frequency and severity of migraines. ^{6 7 8 9 10}

Who Is on the Research Team?

Ipsen Medical Director

Principal Investigator

Ipsen

Are You a Good Fit for This Trial?

Adults aged 18-80 with a history of episodic or chronic migraines, diagnosed before age 50 and lasting at least 12 months. Participants must have tried one migraine prevention treatment, be able to consent, and record their headache frequency in an eDiary. Those with chronic migraines should have ≥15 headache days per month; for episodic migraines ≤14 headache days but ≥6 migraine days are required.

Inclusion Criteria

Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF. Participant has provided written informed consent and signed privacy/data protection documentation

I have tried at least one preventive treatment for my migraines.

I have been diagnosed with episodic migraines and meet the headache frequency criteria.

Exclusion Criteria

Actively suicidal patients

I am not pregnant, nursing, or if capable of becoming pregnant, I agree to use contraception.

I am taking more than one approved preventive migraine treatment.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment - Step 1

Participants receive IPN10200 or placebo injections in muscles of the head, face, and neck. Safety is monitored throughout the 36 weeks.

36 weeks

Treatment - Step 2

New eligible participants are divided into groups based on diagnosis and receive Dose A, Dose B, or placebo. Monitored for efficacy and safety until Week 36.

36 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• IPN10200

Trial Overview

The trial is testing IPN10200's ability to prevent severe headaches in adults by injecting it into the muscles of the head and neck. It will determine the safest and most effective dose for reducing migraine frequency as recorded in participants' daily electronic diaries over up to 44 weeks.

How Is the Trial Designed?

Group I: Step 2- EM group IPN10200 Dose B Experimental Treatment 1 Intervention

Dose B will be administered to the participants in a single treatment cycle

Group II: Step 2- EM group IPN10200 Dose A Experimental Treatment 1 Intervention

Dose A will be administered to the participants in a single treatment cycle.

Group III: Step 2- CM group IPN10200 Dose B Experimental Treatment 1 Intervention

Dose B will be administered to the participants in a single treatment cycle

Group IV: Step 2- CM group IPN10200 Dose A Experimental Treatment 1 Intervention

Dose A will be administered to the participants in a single treatment cycle

Group V: Step 1 - Cohort 2 - IPN10200 Experimental Treatment 1 Intervention

Participants will receive IPN10200 dose B through injections at Day 1.

Group VI: Step 1 - Cohort 1- IPN10200 Experimental Treatment 1 Intervention

Participants will receive IPN10200 dose A through injections at Day 1.

Group VII: Step 1 - Cohort 1 - Placebo Placebo Group 1 Intervention

Participants will receive placebo through injections at Day 1.

Group VIII: Step 1 - Cohort 2 - Placebo Placebo Group 1 Intervention

Participants will receive placebo through injections at Day 1.

Group IX: Step 2- CM group placebo Placebo Group 1 Intervention

Placebo will be administered to the participants in a single treatment cycle

Group X: Step 2- EM group placebo Placebo Group 1 Intervention

Placebo will be administered to the participants in a single treatment cycle

IPN10200 is already approved in United States, European Union for the following indications:

Approved in United States as Botox for:

• Chronic migraine
• Other indications not related to IPN10200 specifically

Approved in European Union as Botox for:

• Chronic migraine
• Other indications not related to IPN10200 specifically

Who Is Running the Clinical Trial?

Ipsen

Lead Sponsor

Trials

358

Recruited

74,600+

David Loew

Ipsen

Chief Executive Officer since 2020

BA in Business Administration and MBA from the University of St. Gallen, Switzerland

Sandra Silvestri

Ipsen

Chief Medical Officer since 2023

MD, PhD

Published Research Related to This Trial

In a study of 19 Japanese adults with frequent migraines, Botulinum Toxin Type A (BoNT-A) injections significantly reduced migraine-related disability, as measured by the MIDAS score, two months after treatment.

No serious side effects were reported, indicating that BoNT-A is a safe option for migraine prophylaxis, although further randomized controlled trials are needed to confirm its efficacy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Botulinum toxin type A for migraine prophylaxis in the Japanese population: an open-label prospective trial. Suzuki, K., Iizuka, T., Sakai, F.[2019]

In a 24-month study involving 641 adults with chronic migraine, treatment with onabotulinumtoxinA significantly reduced headache days from an average of 20.6 to 7.4 days, demonstrating its effectiveness as a preventive treatment.

The treatment was generally well-tolerated, with 18.3% of patients reporting mild to moderate adverse drug reactions, and no new safety concerns were identified, indicating a favorable safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. Ahmed, F., Gaul, C., García-Moncó, JC., et al.[2020]

Botulinum toxin type A is a well-tolerated preventive treatment for chronic migraine, with over a decade of established use, and its unique mechanism of action differs from newer CGRP-targeting monoclonal antibodies, suggesting both treatments will coexist in migraine management.

Future research may lead to the development of new botulinum toxin types that specifically target sensory pain neurons, potentially enhancing its effectiveness in treating chronic migraine and other headache disorders.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Botulinum Toxin in the Treatment of Headache. Becker, WJ.[2021]

Onabotulinumtoxin A is an effective treatment for chronic migraine, approved since 2010, and works by targeting the release of neurotransmitters and neuropeptides involved in headache mechanisms.

While onabotulinumtoxin A is associated with more treatment-related adverse events than a placebo, it has fewer side effects compared to the oral medication topiramate, indicating a relatively favorable safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Corasaniti, MT., Bagetta, G., Nicotera, P., et al.[2023]

An open-label study was conducted to assess the safety and effectiveness of botulinum toxin type A injections in patients with chronic migraine who did not respond to at least three different prophylactic medications.

The study highlights the potential of botulinum toxin type A as a treatment option for chronic migraine sufferers, particularly those who have not found relief with standard preventive therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Botox therapy for refractory chronic migraine. Conway, S., Delplanche, C., Crowder, J., et al.[2010]

Botulinum toxin A significantly reduces the number of headaches per month in adults with chronic daily headaches and chronic migraines, with a reduction of about 2 headaches per month in both groups based on pooled analyses of 3 and 5 studies, respectively.

However, botulinum toxin A does not show a significant effect on episodic migraines or chronic tension-type headaches, and it is associated with some side effects like blepharoptosis and neck stiffness compared to placebo.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. Jackson, JL., Kuriyama, A., Hayashino, Y.[2022]

Botulinum toxin treatment significantly reduces the frequency of migraine days by an average of 2 days per month in adults with chronic migraines, based on a systematic review of 28 trials involving 4190 participants.

While botulinum toxin has a higher relative risk of treatment-related adverse events compared to placebo, it shows a lower risk compared to other active treatments, indicating a favorable safety profile for chronic migraine management.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. Herd, CP., Tomlinson, CL., Rick, C., et al.[2020]

OnabotulinumtoxinA (BOTOX) significantly reduces the frequency of headache days in adults with chronic migraine, showing a mean decrease of 8.4 days compared to 6.6 days for placebo over 24 weeks, indicating its efficacy as a prophylactic treatment.

The treatment was generally safe and well tolerated, with most adverse events being mild to moderate, and only a small percentage of patients discontinuing due to side effects (3.8% for onabotulinumtoxinA vs. 1.2% for placebo).

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Dodick, DW., Turkel, CC., DeGryse, RE., et al.[2018]

OnabotulinumtoxinA (BOTOX®) significantly reduces the number of headache days and the need for acute headache medication in chronic migraine patients, with improvements observed at approximately 24 and 52 weeks based on data from 44 studies involving real-world effectiveness.

The treatment also enhances quality of life, as indicated by improvements in the Migraine-Specific Quality-of-Life score, and shows a response rate of over 46% for at least a 50% reduction in migraine days, confirming its efficacy as a preventive treatment for chronic migraines.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data. Lanteri-Minet, M., Ducros, A., Francois, C., et al.[2023]

Botulinum toxins are effective preventive treatments for patients with moderate to severe migraines, particularly for those who do not respond to traditional medications or experience intolerable side effects.

Studies have shown significant reductions in migraine frequency, severity, and duration with botulinum toxin treatments, especially in patients with the most severe headaches, highlighting the need for further research to optimize treatment protocols.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Botulinum toxins in the treatment of migraine and tension-type headaches. Winner, P.[2019]

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC9693763/

Effectiveness of onabotulinumtoxinA (BOTOX®) for the ...

At ∼24 weeks onabotulinumtoxinA showed total Migraine Disability Assessment score of 44.74 [28.50, 60.99] and ≥50% reduction in migraine days response rate of ...

2.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/20487038/

OnabotulinumtoxinA for treatment of chronic migraine

OnabotulinumtoxinA resulted in significant improvements compared with placebo in multiple headache symptom measures, and significantly reduced headache-related ...

3.

clinicaltrials.gov

clinicaltrials.gov/study/NCT04578782

NCT04578782 | Efficacy of OnabotulinumtoxinA in Migraine

At six months, after two cycles of treatment, those treated with Botox® had on average eight less days of headache each month. After 12 months, 70% of those ...

4.

thejournalofheadacheandpain.biomedcentral.com

thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-019-1030-z

Real-world effectiveness of onabotulinumtoxinA treatment for ...

Patients also experienced reductions in monthly severe headache days, monthly migraine days, HIT-6 scores, missed days of work or study, and use ...

5.

bmjopen.bmj.com

bmjopen.bmj.com/content/9/7/e027953

Cochrane systematic review and meta-analysis of ...

Conclusions In chronic migraine, botulinum toxin reduces migraine frequency by 2 days/month and has a favourable safety profile. Inclusion of medication overuse ...

6.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC5367647/

Botulinum toxin in the management of chronic migraine

It has been shown that onabotulinumtoxinA is effective in the reduction of headache frequency and severity in patients with CM. Treatment is well tolerated by ...

7.

botoxchronicmigraine.com

botoxchronicmigraine.com/

BOTOX® (onabotulinumtoxinA) - Chronic Migraine Treatment

Learn about BOTOX® for adults with Chronic Migraines (15+ headache days a month). See full Safety and Product Info, including Boxed Warning.

8.

withpower.com

withpower.com/trial/phase-2-chronic-migraine-9-2024-cf9ff

IPN10200 for Migraine Prevention (MERANTI Trial)

Research shows that Onabotulinumtoxin A, a form of Botulinum toxin, is generally safe for treating chronic migraines, with fewer side effects than some oral ...

9.

brieflands.com

brieflands.com/journals/amhsr/articles/139223

Safety Profile of Botulinum Toxin for Migraine Headache ...

Nowadays, botulinum toxin is used for migraine prophylaxis, and a wide range of adverse effects (AEs) are reported after administration.

10.

clinicaltrials.gov

clinicaltrials.gov/study/NCT01662492

A Study Using Botulinum Toxin Type A as Headache ...

To evaluate the efficacy and safety of Botulinum Toxin Type A versus placebo (normal saline) as headache prophylaxis in adolescents (children 12 to 17) with ...